Emerging evidence suggests that SGLT2 inhibitors may also affect hepatic lipid metabolism, making them a promising therapeutic option for reducing LFC in patients with NAFLD/MASLD [21]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.